Literature DB >> 16985870

Permanent prostate brachytherapy: the significance of postimplant dosimetry.

W Robert Lee.   

Abstract

Recent developments in imaging science and treatment-planning software allow for accurate postimplant dosimetric assessment in all patients after prostate brachytherapy. This article reviews the available data correlating cancer control and morbidity with dosimetric quantifiers obtained from postimplant dosimetric assessment after prostate brachytherapy. Continued collection of dosimetric data in patients treated with prostate brachytherapy will allow for further refinements in the technique, leading to continued high rates of cure with increasingly lower rates of morbidity.

Entities:  

Year:  2004        PMID: 16985870      PMCID: PMC1472865     

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


  33 in total

1.  Postimplant analysis of transperineal interstitial permanent prostate brachytherapy: evidence for a learning curve in the first year at a single institution.

Authors:  W R Lee; A F deGuzman; R L Bare; M G Marshall; D L McCullough
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-01-01       Impact factor: 7.038

2.  Source placement error for permanent implant of the prostate.

Authors:  P L Roberson; V Narayana; D L McShan; R J Winfield; P W McLaughlin
Journal:  Med Phys       Date:  1997-02       Impact factor: 4.071

3.  Long-term results of retropubic permanent 125iodine implantation of the prostate for clinically localized prostatic cancer.

Authors:  M J Zelefsky; W F Whitmore
Journal:  J Urol       Date:  1997-07       Impact factor: 7.450

4.  Rectal dosimetric analysis following prostate brachytherapy.

Authors:  G S Merrick; W M Butler; A T Dorsey; J H Lief; H L Walbert; H J Blatt
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-03-15       Impact factor: 7.038

5.  A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy.

Authors:  L Potters; Y Cao; E Calugaru; T Torre; P Fearn; X H Wang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-07-01       Impact factor: 7.038

6.  Erectile function after permanent prostate brachytherapy.

Authors:  Gregory S Merrick; Wayne M Butler; Robert W Galbreath; Robin L Stipetich; Laurie J Abel; Jonathan H Lief
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-03-15       Impact factor: 7.038

7.  Brachytherapy for clinically localized prostate cancer: results at 7- and 8-year follow-up.

Authors:  H Ragde; J C Blasko; P D Grimm; G M Kenny; J Sylvester; D C Hoak; W Cavanagh; K Landin
Journal:  Semin Surg Oncol       Date:  1997 Nov-Dec

8.  The dosimetry of prostate brachytherapy-induced urethral strictures.

Authors:  Gregory S Merrick; Wayne M Butler; Bryan G Tollenaar; Robert W Galbreath; Jonathan H Lief
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-02-01       Impact factor: 7.038

9.  Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer.

Authors:  R G Stock; J Kao; N N Stone
Journal:  J Urol       Date:  2001-02       Impact factor: 7.450

10.  125I versus 103Pd for low-risk prostate cancer: preliminary PSA outcomes from a prospective randomized multicenter trial.

Authors:  Kent Wallner; Gregory Merrick; Lawrence True; Steven Sutlief; William Cavanagh; Wayne Butler
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-12-01       Impact factor: 7.038

View more
  2 in total

1.  Nanoparticle-based brachytherapy spacers for delivery of localized combined chemoradiation therapy.

Authors:  Rajiv Kumar; Jodi Belz; Stacey Markovic; Tej Jadhav; William Fowle; Mark Niedre; Robert Cormack; Mike G Makrigiorgos; Srinivas Sridhar
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-02-01       Impact factor: 7.038

2.  Evaluation of intraoperative magnetic resonance imaging/ultrasound fusion optimization for low-dose-rate prostate brachytherapy.

Authors:  Stephen Abel; Paul Renz; Olivier Gayou; Jie Tang; E Day Werts; Mark Trombetta
Journal:  J Contemp Brachytherapy       Date:  2017-08-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.